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Hantaan virus (HTNV) in the Hantavirus genus,
family Bunyaviridae, is themajor cause of severe
hemorrhagic fever with renal syndrome (HFRS).
We prepared a combinatorial phage display
library of human Fabs toHTNV fromRNAextract-
ed from the blood lymphocytes of a convalescent
HFRS patient. We selected two G1 glycoprotein-
specific clones and one nucleocapsid protein
(N)-specific clone from the Fab library for further
studies. The human Fab antibodies were con-
verted to IgG form in baculovirus/insect cells
system by using cassette vectors that we devel-
oped earlier. Characterization of the recombinant
antibodies revealed that the twoG1-specific IgGs,
could bind to and neutralize HTNV but not Seoul
virus (SEOV). The N-specific IgG did not neutra-
lize either HTNV or SEOV. Sequence analysis
revealed that the two G1-specific clones differed
by only one predicted amino acid in their
complementarity determining regions, CDR3.
Epitope mapping studies were carried out with
one of the two G1-specific clones and synthetic
peptides representing portions of HTNV G1.
Results indicated that the recombinant antibody
recognizes the core amino acid sequence
LTKTLVIGQ, which is found near the C-terminus
of HTNVG1. These results are the first to define a
neutralizing epitope on the G1 protein of HTNV
using an antibody derived from an HFRS patient.
J. Med. Virol. 69:99–107, 2003.
 2003 Wiley-Liss, Inc.
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INTRODUCTION
Hantaviruses cause two life threatening diseases:
hemorrhagic fever with renal syndrome (HFRS) and
hantavirus pulmonary syndrome (HPS). At least four
hantaviruses cause HFRS: Hantaan virus (HTNV),
Seoul virus (SEOV), Dobrava virus (DOBV), and
Puumala virus (PUUV) [Schmaljohn and Hjelle, 1997].
The viruses are found throughout Eurasia, with China
having the greatest number of cases [Hooper and Li,
2001].HTNV is responsible for themajority of the severe
HFRS cases occurring in China.
Protective immunity to hantaviral infections is
thought to correlate with neutralizing antibody re-
sponses to the viral G1 and G2 envelope glycoproteins
[Arikawa et al., 1989, 1992]. Most of the antigenic
determinants on G1 and G2 of HFRS-causing hanta-
viruses are believed to be conformational, as reflected by
the high cysteine content of both proteins and the poor
reactivity of HFRS patient sera with denatured G1 or
G2. Only a few epitope mapping studies of hantaviral
envelope proteins have been reported. A competitive
binding study of 24mousemonoclonal antibodies (Mabs)
revealed at least nine distinct, partially overlapping
antigenic sites on HTNV G1 and G2 [Arikawa et al.,
1989]. In subsequent studies with the same Mabs, se-
quence analysis of the genomes of Mab escape mutants
revealed that noncontiguous amino acids form neutra-
lizing epitopes (i.e., conformational epitopes) on the
envelope proteins [Wang et al., 1993; Kikuchi et al.,
1998]. Conformational, neutralizing epitopes were also
identified on PUUV using phage display to express
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random peptides and by reacting the expression pro-
ductswith twoG2-specificMabs toPUUV[Salonenetal.,
1998, Heiskanen et al., 1999, Nicacio et al., 2000]. Thus,
evidence to date suggests that neutralizing epitopes of
the G1 and G2 proteins of HFRS-causing hantaviruses
are frequently conformational.
We describe selection and characterization of a
neutralizing human IgG antibody to HTNV G1 derived
fromRNA extracted from lymphocytes of a convalescent
HFRS patient by using phage display and recombi-
nant antibody technology. In addition we report, for the
first time, fine epitopemapping of a human neutralizing
antibody to the G1 protein of HTNV and identify its
antigen-binding domain.
MATERIALS AND METHODS
Viruses, Cells, Lymphocytes, and Mabs
The strains of HTNV and SEOV used in this study
were described previously and include HTNV strains
76–118, A9, 84Fli, Chen, H5 and SEOV strains HR-80–
39, L99, R22, HB55 [Liang et al., 1994]. Viruses were
propagated in Vero-E6 cells (ATCC, Rockville, MD;
C1008 CRL 1586). The human lymphocytes used for
RNA extractionwere isolated fromaHFRSpatient from
Anhui Province, China, during a 2-month convalescent
phase. The mouse Mabs to HTNV G1 (6D4) and G2
(11E10) were described earlier [Arikawa et al., 1989].
Construction, Panning, and Screening of a
Human Antibody Phage-Display Library
TheHFRSpatient blood lymphocyteswere purified on
a Ficoll gradient. Total cellular RNAwas extracted from
pelleted lymphocytes by using Trizol reagent (GIBCO
BRL, Gaithersburg, MD) and cDNA was synthesized
by using oligo (dT) primers and reverse transcriptase.
The heavy chain Fd and light chain genes were am-
plified from the cDNA by polymerase chain reaction
(PCR) and cloned sequentially into the phagemid vector
pComb3 as described elsewhere [Barbas et al., 1991]
The human antibody phage library was constructed
after transformation of E. coli followed by the rescue of
helper phage as described previously [Barbas et al.,
1991]. The antibody phage library was selected by
3–4 rounds of alternative panning on purified HTNV
virions [Schmaljohn et al., 1983] or on HTNV glycopro-
teins captured with mouse Mabs. Briefly, for the first
round of panning, 6–8 wells of a 96-well immunoplate
were coatedwith 0.5–1 mg/well of purifiedHTNV (strain
76–118) overnight at 48C. For the second round of pan-
nings, the plates were first coated with 0.5–1 mg/well
of a mixture of Mabs 6D4 (G1-specific) and 11E10
(G2-specific), followed by addition of a lysate of HTNV-
infected Vero-E6 cells. The lysate was prepared by
treating Vero-E6 cells infected for 7–8 days with HTNV
with 2% NP-40. Nuclei were removed from the lysates
by centrifugation and the lysatewas dilutedwith 0.02M
phosphate buffered saline (PBS) containing 4% skim
milk. Lysate (100 ml) was added to the antibody coated
plates and plates were incubated at 378C for 2 hr. The
plates were then washed with 0.02 M PBS containing
0.05% Tween-20 and blocked with PBS containing 4%
skim milk, then 100 ml of the phage libraries was added
to the plates and panning was continued as described
previously [Barbas et al., 1991]. After 3 or 4 rounds of
panning, the humanFab antibody geneswere expressed
in E. coli and the Fab were screened by ELISA and an
immune fluorescence assay (IFA) as described below.
Sequence Analysis of the Variable
Regions of the Fabs
Nucleic acid sequencing was carried out with the
ABI PRISM Dye Terminator Cycle Sequencing Ready
Reaction kit (Perkin Elmer, Inc., Boston, MA) and the
primers: 50CCGCGGTGGCGGCCGCAA30 for the VH
gene of the heavy chains and the primer 50AAACTAGC-
TAGTCGCCAAGGA30 for the VL of the light chains.
Sequences were analyzed by aligning to human immu-
noglobulin sequences present in GenBank and the CDR
regions were determined with the V-Base program
(Center for Protein Engineering, Cambridge, UK).
Construction and Expression of Complete IgG
The VH and VL or Fab genes of three of the human
Fabs selected from the phage library were cloned into
IgG expression cassette vectors pAc-L-CH3, pAc-K-CH3
or pAc-L-Fc, as described previously, such that in-frame
ligations to a human Fc region were obtained [Liang
et al., 2001]. The resulting expression vector DNA con-
taining heavy and light chain genes were transfected
into SF9 insect cells, and recombinant baculoviruses
were prepared by homologous recombination using the
Baculo-Gold transfection kit (Pharmingen, San Diego,
CA) according to the manufacturer’s instructions.
To assay expression, IFA was carried out on SF9 cells
infected with plaque purified recombinant baculo-
viruses using FITC conjugated anti-human Fc-specific
antibodies. Secreted, recombinant human IgG antibo-
dies were detected in the supernatants of infected
SF9 cells by a conventional capture ELISA, using goat
anti-human IgG Fab as a capture reagent and HRP
conjugated anti-human Fc for detection.
ELISA
ELISA were carried out to screen crude Fab or IgG
antibody preparations, determine the binding avidities
of the Fab or IgG antibodies to hantaviruses, and for
antigenic analysis of Fab or IgG antibodies to various
hantaviruses. Direct ELISA was carried out by coating
eachwell of a 96-well plate with approximately 0.5–1 mg
of sucrose gradient purified HTNV diluted in 0.01 M
sodium carbonate buffer, pH.8.6. The plates were block-
ed with 4% skim milk in PBS, after which the crude or
purified Fab or IgG antibody preparations were added.
Wellswerewashed and incubatedwithHRP-conjugated
anti-human Fab or anti-human Fc (Sigma, St. Louis,
MO) followed by TMB substrate for color development.
Antibody capture ELISA was carried out by coating
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plates with approximately 0.5 mg/well, of mouse Mabs
to HTNV G1 or G2(6D4 or 11E10) or N (L13F3). The
plateswerewashed three timeswithPBS-0.02%Tween,
followed by infected cell lysates prepared by treatment
with NP40 as described above. After washing, the test
Fab or IgG antibody preparations were added to the
wells and subsequent steps were the same as those
described for the direct ELISA.
Immunofluorescence Assays (IFA)
The HTNV, SEOV, and PUUV IFA antigen slides
were purchased from Progen (Heidelberg, Germany) or
were prepared in our laboratory using standard condi-
tions [Lee et al., 1999]. Briefly, Vero-E6 cells were
infected with hantavirus for 7–14 days. The infected
cells were digested with trypsin-EDTA (GIBCO-BRL)
and washed with PBS once, then resuspended in PBS
at the concentration around 1 106 cells/ml. The cells
were fixed on 10- or 12-well slides with cold acetone at
208C for at least 30 min, then were dried and kept at
708C for next steps. DOBV antigen slides were kindly
provided by Dr. T. Avsic-Zupanc, Institute of Microbiol-
ogy and Immunology, Lubjana, Slovenia. In addition to
these slides prepared with authentic hantaviral anti-
gens, for HTNV and SEOV screening we prepared IFA
slides from recombinant baculovirus-infected SF9 cells.
Briefly, SF9 cells cultured in T25 flasks were infected
with recombinant viruses expressingHTNV or SEOVM
segments for 3–4 days. The infected cells were washed
and resuspended in PBS then fixed on 10- or 12-well
slideswith acetone at room temperature for 10min. Cell
culture supernatants of SF9 cells infected with recom-
binant baculoviruses expressing human IgG antibodies
to G1 and NP were incubated with the slides described
above at 378C for 30 min. Bound antibodies were
detected with FITC conjugated anti-human Fab and
human Fc antibodies.
Radioimmunoprecipitation of HTNV
with the Recombinant Antibodies
Confluent monolayers of Vero-E6 cells in T25 flasks
were infected with 2 ml (0.5 106 PFU) of HTNV
strain 76–118. Twenty-four hours postinfection, the
cell culture medium was removed and replaced with
cysteine-and methionine-free Eagles’ Minimal Essen-
tial medium containing 2% FBS, and incubated for 1 hr
at 378C. Cells were radiolabeled with 200 mCi of 35S
Promix (Amersham, Buckinghamshire, UK) per flask
for 4 hr. The cells were lysed on ice with 1ml of cell lysis
buffer composed of pH 8.0 TNE, then centrifuged to
remove the nuclei. The radiolabeled HTNV proteins
were immunoprecipitated bymixing 100 ml of cell lysate
with100ml of aHFRSpatient serumor the supernatants
of SF9 cells infected with recombinant baculoviruses
expressing human antibodies. After incubation at 48C
overnight, protein G-Sepharose 4B (Sigma) was added
and the mixture was shaken at 48C for 3 hr. The beads
with immunoprecipitated proteins were washed 3 times
with lysis buffer containing 1% Zwittergent and once
with 0.1 M Tris-HCl, 1 mM EDTA, then resuspended
in 2 regular SDS-PAGE loading buffer and analyzed
by SDS-PAGE as described previously [Schmaljohn
et al., 1983].
Preparation and Purification of IgG Antibodies
The methods for the preparation and purification of
recombinant baculoviruses expressing human IgG
antibodies has been described in detail [Liang et al.,
2001]. Briefly, supernatants from the recombinant
baculovirus-infected SF9 or H5 insect cells were clari-
fied and applied to Protein-G Sepharose 4B affinity
columns (Sigma Chemical Co., St. Louis, MO), washed,
eluted, neutralized and finally desalted by passing
through a desalting column. IgG concentrations were
detected by UV spectrophotometer and calculated
according to the equations of protein quantitation from
Harlow andLane [1988] and adjusted to a concentration
of 200–500 mg/ml. Under reducing and nonreducing
conditions 2 mg of purified IgG antibody was examined
by SDS-PAGE as described previously [Liang et al.,
2001].
Plaque Reduction Neutralization Test (PRNT)
PRNTs for HTNV and SEOV were carried out using
methods described previously [Schmaljohn et al., 1983].
Briefly, Vero-E6 cells were cultured in 24-well plates
for one week. The purified human recombinant Fab and
IgG antibodies were standardized to 100 mg/ml and
diluted serially in two-fold increments. Aliquots of each
antibody dilution (100 ml each) were incubated with 100
PFUofHTNVorSEOVat48Covernight.Virus-antibody
mixtures were applied to the cell monolayers and
incubated at 378C for 1 hr, then overlaid with 0.6%
agarose-EMEM.After incubationat378C,5%CO2 for7–
8 days, an overlay of 0.6% agarose-neutral red EMEM
was added to the plates. The percent neutralization of
antibodies was calculated by comparing the maximum
average plaque numbers from the virus control and the
plaque numbers from the antibody dilutions. Neutraliz-
ing activitywas determined by 50% reduction of plaques
as compared to the control.
Peptide Scan of the Epitope of Human
Recombinant Antibody IgG100
Peptides (15mers) covering the entire amino acid
sequence of G1 of HTNV (strain 76–118, GenBank
accession number M14627) were synthesized with a
ASP222 machine on activated membranes using fMOc
protected amino acid derivatives (Sigma–Genosys,
Cambridgeshire, UK) according to the procedure de-
scribed previously [Frank, 1992]. An immunoassay was
carried out using a protocol published previously
[Bluthner et al., 2000], with somemodifications. Briefly,
themembraneswith synthesized peptides on themwere
washed three times for 10 min in TBS buffer (10mM
Tris/HCl, pH 7.6, 150 mM NaCl). Nonspecific binding
sites were blocked by overnight incubation in TBS-2%
milk at 48C. The membranes were washed once with
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TBS-0.2% Tween-20 buffer, and were incubated with
antibody dilutions (5 m/ml) in TBS-2%-powdered skim
milk for 2 hr. The unbound antibodies were removed by
washing the membrane three times with TBS-T, and
afterwards three times in TBS for 5 min per wash.
Horseradish peroxidase (HRP)-conjugated goat anti-
human IgG antibody was added and the membranes
incubated at room temperature, then washed as above.
ECL Western blotting detection reagents were used to
visualize the proteins (Amersham).
Fine Mapping of IgG 100 by Mutational
Analysis and Structure Prediction
The major epitope containing the peptide GQRKVIL-
TKTLVIGQ was analyzed by glycine-walking. Each
amino acid except the glycine in the peptides was
replaced by glycine individually, and the glycine was
replaced by alanine. The resulting mutated peptides
were incubated with the human IgG antibody IgG100
and analyzed as described above. Secondary structure
prediction of the peptide was carried out with the
program PEPTIDE STRUCTURE from the HUSAR
package (Version 5) of the German Cancer Research
Center (Heidelberg, Germany).
RESULTS
Selection and Initial Characterization
of HTNV-Specific Fab
A combinatorial antibody library was constructed
from RNA extracted from the blood lymphocytes of a
convalescent HFRS patient exhibiting high levels of
HTNV-specific antibodies (data not shown). PCR-
amplified human heavy and light chain Fab genes were
inserted into the phagemid vector pComb3 and the Fabs
were displayed on the surface of VCS M13 filamentous
phage. The library was panned and screened against
purified HTNV or viral glycoproteins selected from an
infected cell lysate by antibody capture. Fab antibody
clones taken from 3–4 rounds of panning were chosen
for further study by their reactivity in ELISA. Ten Fab
clones were selected and characterized for their specific
binding properties and genetic information (Table I).
The Fab preparations were screened by ELISA using
plates coated with purified HTNV, or with G or N
capturedwith specificMabs, asdescribed in theMethods
section. All 10 Fab clones reacted with purified HTNV;
of these, eight clones (AH7, AH8, AH23, AH55, AH56,
AH95, AH100, and AH105) recognized HTNV glycopro-
teins and two clones (AH30, AH34) recognizedNP in the
variousELISA (Table I). Sequenceanalysis of the 10Fab
clones showed the glycoprotein-specific Fab to be very
similar except AH 23 showed 1 amino acid change with
others in the VL CDR1 regions. All of them were
composed of IgG1 Fd heavy chains and lambda light
chains. Similarly, the two N-specific clones (AH30,
AH34) had nucleotide sequences encoding IgG1 Fd
heavy chains and kappa light chains that were very
similar (Table I). Moreover, the deduced amino acid se-
quences of the heavy and light chain complementarity-
determining region, CDR3, which is known to be the
most variable region in antibodymolecules, were nearly
identical for the Fabs reactive with glycoproteins.
Likewise, the CDR3 of the two N-reactive Fabs were
nearly identical. Therefore, it is likely that the G and N
Fab clones were derived from only two parent clones.
Linkage of Selected Fab Genes to
Human IgG Fc and Expression
by Recombinant Baculoviruses
According to the sequences and the antigen binding
properties of the above Fab clones, the variable
heavy (VH) and light (VL) genes of Fab clones AH100
(G1-reactive), and AH30 (N-reactive), and the Fd and
TABLE I. Characteristics of Fab Clones Selected From Phage Display Antibody Libraries
Fab clones IFAa
ELISA (OD490)
PRNT (%)e CDR3 (VH)f CDR3 (VL)fVirionb Nc G1þG2d
AH7 þ 0.45 0.02 0.53 <10 YYCARGDSSGYYPLNWFG YYCETWDSSLEL–WYFGG
AH8 þ 0.56 0.01 0.67 25 YYCARGDSSGYYPLNWFG YYCETWDSSLSGLWYFGG
AH23 þþ 0.89 0.02 0.82 45 YYCARGDSSGYYPLNWFG YYCETWDSSLECLWYFGG
AH30 þþþþ 0.68 1.02 0.02 <10 YYCARGHEHWSILDYWFG YICQHFGRSQYTFGG
AH34 þþþþ 0.72 0.99 0.00 <10 YYCARGHEHWSILDYWFG YICQQFGRSQYTFGG
AH55 þ 0.48 0.01 0.53 35 YYCARGDSSGYNPLNWFG YFCGTWDKSLECLWYFGG
AH56 þ 0.59 0.00 0.45 <10 YYCARGDSSGYNPLNWFG YFCGTWDKSLECLWYFGG
AH95 þþ 0.93 0.01 0.86 38 YYCARGDSSGYNPLNWFG YYCETWDSSLECLWYFGG
AH100 þþ 0.97 0.00 0.92 55 YYCARGDSSGYNPLNWFG YYCETWDSSLECLWYFGG
AH105 þ 0.93 0.05 0.95 34 YYCARGDSSGYNPLNWFG YYCETWDSSLECLWYFGG
aIFA: Immunofluorescence assays were performed on HTNV-infected Vero E6 cells as described in Methods, (þ) to (þþþþ) indicates the relative
intensity of fluorescence.
bVirion, Sucrose gradient purified HTNV.
cCapture ELISA performed with HTNV N antigen from infected Vero-E6 cells.
dCapture ELISA performed with HTNV G1 and G2 antigen from infected Vero-E6 cells.
ePRNT values represent the average percent reduction in number of plaques compared to a negative control.
fPartial amino acid sequences of the VH and VL regions of 10 Fab clones, the CDR3 region of VH and VL were indicated as underlined.
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light chain genes of Fab clone AH23 (G1-reactive) were
selected and cloned individually into IgG baculovirus-
expression cassette vectors pAc-L-CH3, pAc-K-CH3
(designed for cloning of scFv gene)and pAc-L-Fd
(designed for cloning Fab genes) as described previously
[Liang et al., 2001] Recombinant baculoviruses were
prepared by homologous recombination using the
Baculo-Gold transfection kit (Pharmingen) according
to the instructions given by the supplier. The human
recombinant intact antibodies to HTNV G1 (AH100IgG
and AH23IgG) and N (Ah30IgG) were expressed in
SF9or High 5 (H5) insect cells after the infection of the
recombinant baculoviruses. The expressed IgG antibo-
dies were purified and concentrated to 150–200 mg/ml.
SDS-PAGE analysis of AH100IgG (IgGl) and AG30IgG
(IgGk) revealed that antibody products expressed by the
baculovirus/insect cellswere of the expected sizes for the
complete heavy and light chains of IgG under reducing
(about 50 kD and 25 kD) and nonreducing (150 kD)
conditions (Fig. 1A). AH23IgG showed the same electro-
phoresis mobility under above two conditions (Data
not shown). These results demonstrate that the baculo-
virus-expressed, recombinant human IgG antibodies
produced in insect cells were correctly assembled and
secreted as authentic heterodimeric immunoglobulins.
Characterization of Selected Human
Recombinant Antibodies to HTNV
To identify the binding specificity of the human
recombinant antibodies, clarified supernatants from
recombinant baculovirus-infected SF9 cells were as-
sayed by immunoprecipitation, and IFA. The human
antibodies AH100IgG and AH23IgG immunoprecipi-
tated radiolabeledHTNVG1 andAH30IgG precipitated
HTNVN (Fig. 1B). IFA was carried out with AH100IgG
on HTNV-infected Vero-E6 cells or insect cells infected
with the recombinant baculovirus expressing HTNV
glycoproteins [Shi et al., 1995] confirmed the HTNV
binding specificities (Fig. 2). To investigate whether
the G1 specific human antibodies (AH 100IgG and
AH23IgG) bind to only HTNV or are cross-reactive with
otherHFRS-causing hantaviruses, IFA, indirect ELISA
and PRNT were carried out. In these three types of
assays, AH100IgG reacted only with HTNV, and not
with SEOV, DOBV, or PUUV (Table II). As expected,
AH23IgG had nearly the same binding specificity and
neutralizing ability as AH100 IgG (data not shown).
These results confirm that the single amino acid differ-
ence in the VH CDR3 regions of these two antibodies
does not influence their function (Table I). Because of
these findings, we used only AH100 for the remainder of
our studies.
To further evaluate the neutralizing activity and the
binding affinity of AH100IgG, we carried out PRNT
with two HTNV strains, 76–118 and 84Fli, and two
SEOV strains, HR80–90 and L99. AH100 IgG clearly
neutralized both HTNV strains. Approximately 1.25 mg
of the affinity purified IgG was required to achieve 80%
reduction in plaques, and 0.3–0.6 mg was required to
achieve 50% plaque reduction (Fig. 3). Consistent with
the IFA and ELISA results, AH100 did not neutralize
either strain of SEOV. As expected, AH30IgG to HTNV
N did not neutralize either HTNV or SEOV. Further,
indirect ELISA as described in the methods measured
the binding affinity of AH100IgG human antibody.
Approximately 125 ng (about 8108 M) of purified
AH100IgGwas required to yield 72%maximumbinding
(OD value 0.6–0.7 at 490 nm). A minimum of 8–16 ng
(1.071010 M) of antibody was required to bind puri-
fied HTNV strains 76–118 and 84Fli. Additionally, as
expected, AH100 did not bind SEOV (Fig. 4).
Fine Epitope Mapping of AH100IgG
To define the antigenic determinant on HTNV G1
recognized by AH100IgG, peptide-scanning methods
were used. For the initial scanning, 15mer peptides
that overlapped by five amino acids, representing the
entire G1 protein of HTNV, were synthesized on acti-
vated membranes and were probed with affinity puri-
fied AH100IgG as described in Methods section. The
Fig. 1. SDS-PAGE of affinity-purified recombinant human IgG
antibodies to HTNV. A: AH100IgG (lanes A,C) and AH23IgG
(lanes B,D) were purified from recombinant baculovirus infected insect
cells by affinity chromatography. About 0.8–1 mg of each antibody
was analyzed by gel electrophoresis under reducing (lanes A,B) or
nonreducing (lanes C,D) conditions. Proteins were visualized by
staining with Coomassie blue. H2L2, heterodimer of 2 heavy and 2
light chains; H, heavy chain; L, light chain. B: Radiolabeled HTNV
proteinswere immunoprecipitatedwithHFRSpatient serum (laneHP)
or with recombinant human antibodies as indicated above each lane.
The positions of the viral envelope glycoproteins, G1 and G2, and the
nucleocapsid protein, N, are indicated to the left of the autoradiogram.
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antibody was highly reactive to the peptide spot
corresponding to the amino acid sequence QRKVILTL-
VIGQClocatedat aminoacids 438–452 of theG1protein
(data not shown). To identify the precise binding site,
15mer peptides, which overlapped by only one amino
acid, covering the immunoreactive area were synthe-
sized and probed as before. In this assay, the highest
antibody binding was to the peptide GQRKVILTKL-
VIGQ (amino acid 437–451) (Fig. 5). To further define
amino acids crucial to the epitope, the sequence GQRK-
VILTKLVIGQC was subjected to a mutational analysis
by successively replacing each amino acid in the 15mer
pep-tidewith glycine or alanine. Probing of the resulting
peptides with AH100IgG, indicated that the replace-
ment at any position of the sequence LTKTLVIGQ
(amino acid 443–451) led to a substantial decrease in
reactivity (Fig. 6). Glycine or alanine replacements at
other positions (Gln 438, Arg 439, Lys 440, Val 441, and
Cys 451) in the peptide obviously decreased the affinity
of the antibody binding, as indicated by the intensity
of the chemiluminescence signal (Fig. 6). Ile442 seems
TABLE II. Antigenic Analysis of Neutralizing Human Recombinant Antibody AH100IGg by
IFA, ELISA and PRNT of Hantaan and Seoul Viruses
Virus Host Isolation
Assays
IFAa
ELISA
(OD490)
b PRNT (%)c
HTNV
76–118 A. agrarius Korea þþþþ 0.78 95
A9 A. agrarius Jiangsu.C þþþþ 0.63 89
84-Fli Human Shanxi.C þþþþ 0.89 95
Chen Human Anhui.C þþþþ 0.81 92
H5 Human Helong.C þþþþ 0.78 92
Luxu Human Shandong.C þþþ 0.56 NT
B569 Human Shandong.C þþþ 0.62 NT
SEOV
HR-80-39 R. norvegicus Korea — 0.03 —
SR-11 Rat Japan — 0.02 —
L99 R. rosea Jiangxi.C — 0.01 —
R22 R. norvegicus Henan.C — 0.02 —
HB55 Human Henan.C — 0.03 NT
DOBV — NT NT
PUUV — NT NT
aThe AH100IgG antibody tested for all above assays was expressed in High 5 insect cells and the
supernatants were diluted 1:2. HTNV and SEOV antigen slides for IFA were prepared as described in
methods. DOBV antigen slides were kindly provided by Dr. T. Avsic-Zupanc. PUUV antigen slides were
purchased from Progen, Germany. þþþþ,þþþ correspond to approximately 100%, or 75% (respectively)
fluorescent cells per field of assay.
bCapture ELISAs were performed as described in Materials and Methods.
cPlaque Reduction Neutralization Test (PRNT) were performed in 24-well plates as described inMaterials
andMethods. The value shown represents the % neutralization of approximately 35 plaques per well. NT,
not tested.
Fig. 2. Immunofluorescence assay of recombinant human antibody
AH100IgG with HTNV-infected Vero-E6 cells (A) or with HTN M
fragment specific recombinant baculovirus infected SF9 cells. (B) FITC
conjugated anti-human IgG Fc antibodies were used for the detection.
Cell culture supernatants of SF9 cells infected with recombinant
baculoviruses expressing human IgG antibodies to G1 and N were
incubated with the slides at 378C for 30 min. Bound antibodies were
detected with FITC conjugated anti-human human Fc antibodies.
Fig. 3. Plaque-reduction neutralization assay of baculovirus/insect
cell-expressed recombinant human antibodies to HTNV. Serial dilu-
tions of the G1 and N-specific human antibodies AH100IgG and AH30
were assayed with HTNV strains A9, Chen, 76–118(HTN), 84-Fli.
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uninvolved in antibody binding, as indicated by no loss
of reactivity of peptide 6 as compared to that the non-
mutated peptide (Fig. 6). These results suggest that the
neutralizing antibody AH100 recognized a linear epi-
tope in the synthesized peptide spots assay.
DISCUSSION
Phagedisplay and recombinant antibody technologies
have been used successfully to generate human anti-
bodies to a wide range of viral pathogens [Burton and
Barbas, 1994; Parren et al., 2000; Sawyer, 2000].
Generally, antibodies are thought to have evolved to
recognize and eliminate foreign pathogens by targeting
surface molecules. For some viral diseases, the ther-
apeutic use of human-derived antibodies offers an alter-
native to antiviral drug treatment. In addition, human
antibodies provide important tools to explore the molec-
ular basis and mechanisms of viral infection and anti-
viral immune protection. In this study, we used phage
display technology and RNA extracted from the blood of
a convalescent HFRS patient to generate human Fab to
HTNV, the most common cause of HFRS. Because it is
known that neutralizing antibodies can be generated
to both of the viral glycoproteins, G1 and G2, and that
neutralizing antibodies are associated with protective
immunity, we were most interested in obtaining anti-
bodies reactive with G1 or G2. Consequently, we select-
ed our library by panning both on complete virus, and on
envelope protein antigens that were captured with
mouse Mabs to G1 and G2. Despite these procedures,
we selected several Fabs reactive with N, as well as
several reactive with the envelope protein antigens.
Nucleotide sequence analysis of the CDR3 coding re-
gions of 10 selected Fabs revealed only two distinctly
different predicted amino acid sequences, one of which
corresponded to N-reactive Fabs and the other with
Fabs reactive with the envelope glycoproteins. There-
fore, we surmise that all of the Fabs were likely derived
from two parent clones. By radioimmune precipitation,
we determined that all of the envelope-protein reactive
Fabs recognized G1. Of these, we selected two with
neutralizing activity and one of the N-reactive Fabs
for conversion to complete IgG. We next constructed
recombinant baculoviruses expressing complete IgGs
and characterized the expressed antibodies with re-
spect to binding and neutralization of HTNV and other
viruses causing HFRS.
Four hantaviruses are known to cause HFRS of
varying clinical severity, ranging from asymptomatic
infection to fulminate hemorrhagic shock and death.
HTNV and DOBV cause the most severe forms of HFRS
with the highest mortality rates. These viruses are both
Fig. 5. Fine epitope mapping of the neutralizing human recombi-
nant antibody AH100IgG. The epitope region (aa 437–452) was
selected for fine mapping based on results obtained by screening
overlapping peptides corresponding to the entire G1 protein of HTNV
(see Materials and Methods).
Fig. 6. Mutational analysis of aa 437–452. Fifteen peptides were
synthesized; each amino acid of thewild-type (wt) peptidewas replaced
by Glycine or Alanine, as indicated by boxed bold lettering. The
resulting mutated peptides were incubated with the human IgG
antibody IgG100 and analyzed as the methods for Figure 5.
Fig. 4. Binding of recombinant human antibodies AH100IgG (G1-
specific) and AH30IgG (N-specific) to sucrose gradient-purified HTNV,
strains 76–118 and 84Fli, and SEOV, strain L99 as measured by
ELISA. Values are expressed as % of maximum binding of OD value at
490 nm.
Recombinant Antibody to Hantaan Virus G1 Protein 105
carried by Apodemus field mice. SEOV, carried by rats,
and PUUV, carried by Clethrionomys bank voles, cause
serious disease, but less frequent fatalities. The molec-
ular and pathogenic mechanisms responsible for the
variation in clinical severity of HFRS are poorly under-
stood. Likewise, the human immune responses, includ-
ing the exact targets of neutralizing antibodies, are not
well defined. We were able to identify one target of a
human immune response that might be important for
protective immunity. The source of the human G1-
specific antibody that we studied was an HFRS patient
from Anhui province, in southern China. This is an
endemic HFRS region with severe disease typical of
HTNV infection. ELISA analysis of the patient sera
before use in our studies revealed significant neutraliz-
ing activity toHTNV (1:400) by PRNT, and high titers to
N (1:1,280), G1(1:512) and G2 (1:256) (data not shown).
Later IPs also showed the patient has antibodies to both
G1 and G2 (Fig. 1B). Consequently, it is not known why
we did not obtain Fabs reactive with G2. Because this
library was selected from only one patient sample, it is
not likely to be representative of the immune responses
of HFRS patients in general.
Previous studies demonstrated that antibodies to the
G1 proteins of Old World hantaviruses are more type-
specific than those to G2 are, i.e., monoclonal antibodies
to G1 react only with homologous virus, but those to G2
can cross-react with other hantaviruses [Arikawa et al.,
1989; Lundkvist et al., 1991, 1993; Avsic-Zupanc et al.,
1995]. Consistent with these findings, our patient-
derived human recombinant antibody, AH100, recog-
nized HTNV but not SEOV, PUUV, or DOBV in IFA.
Similarly, this antibody recognized and neutralized
HTNV but not SEOV when examined by ELISA and
PRNT. These data may have implications on the design
of an immunotherapeutic approach to HFRS in regions
wheremore than one hantavirus causesHFRS. Itmight
be necessary, for example, to use a cocktail of antibodies
to treat HFRSwhen the infecting virus has not yet been
identified.
To gain a better understanding of the reactivity of the
G1-specific antibody AH100, wemapped its binding site
by reacting it with a series of overlapping peptides
representing theG1 protein ofHTNV. Subsequently, we
carried out sequential single amino acid mutational
analysis to identify specific amino acids involved in
site recognition. The results of our study indicate that
AH100 recognizes a core portion of theG1 epitopewith a
sequence ofLTKTLVIGQ (amino acid 443–451 ofHTNV
G1). The affinity of the antibody binding is increased by
the surrounding amino acids (Gln 438, Arg 439, Lys 440,
Val 441, and Cys 451).
The epitope that we defined for AH100 is located in
the C-terminal hydrophilic region of G1, which may be
exposedon the surface ofHTNV.This epitope is close toa
site (aa 415) where a neutralizing mouse Mab (16D2)
was mapped by using antibody-escape mutants [Wang
et al., 1993]. It is also near a site identified in an at-
tenuated HTNVmutant (mu11E10, aa 515), which was
postulated to be related to virulence in mice [Ebihara
et al., 2000]. This defined epitope is also in line with the
region of DNA segment from aa 399–565 that induced
the neutralizing antibody responses to SNV [Bharadwaj
et al., 1999]. Non-neutralization epitopes have been
mapped to the N-terminal third of the G1 protein of
hantaan virus [Wang et al., 1993], however, the
evidences described above indicated that theC-terminal
third of G1 protein constitute one of major neutrali-
zation epitopes of hantaviruses and may contribute to
bind the virus receptor on infected cells and related to
virus virulence.
Despite our finding that AH100 IgG isHTNV-specific,
we found that the core epitope was mostly conserved
among all four HFRS-causing hantaviruses. One possi-
ble explanation for this is a differing availability of the
site on the virion surface because of protein confor-
mation. We found that there is a conserved N-linked
glycosylation sites Asn-X-Ser nearby the epitope (15 aa
downstream of the epitope); different sugars may con-
tribute to the conformation of the antibody-binding
domain. Alternatively, differences in amino acids ad-
jacent to the epitope may influence the ability of
the antibody to bind to the core epitope. Comparing the
HTNV-derived peptide QRKVILTKTLVIGQC to the
allied peptides derived from SEOV, DOBV, and PUUV
(Table III), the adjacent amino acids to the conserved
TABLE III. Comparison of the Predicted Amino Acid Sequences for Various Hantaviruses at the Defined Binding Site of the
HTNV G1-Specific Antibody AH100IgG
Virus strains Peptide sequencesa Accession number
HTN
76-118, HoJo, A9, HV114 VVYCN437GQRKVILTKTLVIGQ451CIYTI D00376, M14627, U00150, L08753
SEO
HR80-39, SR-11, L99HB55 IVYCN435GQKKTILTKTLVIGQ451CIYTI AB027561, M34882, AF035833, AF035833
DOB
Dobrava VIYCN437GQKKTILTKTLVIGQ451CIYSV L33685
PUU
Sotkama IVYCN447GMKKVILTKTLVIGQ461CIYSV X61034
P360 IVYCN447GLKKVILTKTLVIGQ461CIYTP L087
aTheaminoacid sequencesarenumbered basedon theamino terminal aminoacid sequencededuced forG1andare includedwith thenumbers that
represent the amino acid positions of each peptide. The core amino acid sequences of HTNV G1 defined as the binding epitope for AH100 and the
identical sequences found in deduced amino acid sequences of SEOV, DOBV and PUUVG1 are underlined. The different adjacent amino acids to
the conserved core epitope LTKTLVIGQ are in bold.
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core epitope LTKTLVIGQ revealed differences between
HTNV (Arg 439) and SEOV, DOBV (Lys 437) as well as
PUUV (Lys 449) at the allied position. The binding
signal of AH100IgG to the peptide was decreased signi-
ficantly by mutating the Arg 439 to Glycine (Table III).
A third possibility is that the linear core epitope we
defined is only a part of a conformational epitope. In
support of this theory, we found that AH100 reacted
with intact G1 by immune precipitation, but not by
Western blot (data not shown). Similar findings; i.e.,
that a portion of a conformational epitope can be re-
cognized by an antibody in a highly sensitive assay
involving short linear peptides, have been reported
previously [Roivaine et al., 1991; Heiskanen et al.,
1999]. Furthermore, crystallographic studies on anti-
gen-antibody complexes showed that antibodies may
directly interact with 14–22 amino acids and that 2–5
continuous linear peptides constitute one conforma-
tional antibody binding domain on an antigen [Davis
and Padlan, 1990].
In summary, we generated a type-specific, neutra-
lizing human IgG to HTNV G1 by using phage display
and recombinant antibody technology. This anti-
body and other similar antibodies derived from HFRS
patients may prove useful for immunotherapy or for
studies aimed at defining the human immune responses
to hantaviruses.
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